Clinical Trials Logo

Filter by:
NCT ID: NCT00615953 Suspended - Clinical trials for Growth Hormone Deficiency

American Norditropin Studies - Registry of Growth Hormone (GH) Patients

ANSWERProg
Start date: May 2007
Phase: N/A
Study type: Observational

The Norditropin National Registry is a post-marketing registry of patients using Norditropin therapy. A large body of data will be generated to meet the following Registry Objectives: - To develop a pharmacodynamic model defining the relationship of Norditropin dose to IGF changes, accounting for effects of known or suspected independent variables such as age, gender and puberty - To develop a model defining the relationship of GH dose and IGF exposure to treatment outcomes, accounting for effects of known or suspected independent variables such as age, gender and puberty - To develop a safety model that related GH doses to adverse even occurrence, again accounting for the effects of known or suspected independent variables - To determine the relative predictive values of pre-treatment GH stimulation tests and pre-treatment IGF-I and IGFBP-3 levels

NCT ID: NCT00614757 Suspended - Insulin Resistance Clinical Trials

Insulin Resistance Study

IR
Start date: May 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate how often patients with hepatitis C infection have abnormalities of sugar and fat utilization. Additionally we would like to find out if these abnormalities of sugar and fat utilization are common in other liver diseases, or related to being overweight.

NCT ID: NCT00594750 Suspended - Asthma Clinical Trials

Mechanisms of Exacerbation of Asthma

MECA
Start date: May 2006
Phase:
Study type: Observational

The purpose of this study is to identify the causes of asthma that were not previously suspected, to better understand the effects of inhaled steroids on asthma and to identify new way to treat asthma.

NCT ID: NCT00591682 Suspended - Solid Tumors Clinical Trials

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Start date: November 2007
Phase: Phase 1
Study type: Interventional

Primary Objectives: 1. To determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122 2. To characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122 Secondary Objectives: 1. To determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122 2. To evaluate the preliminary evidence for anti-tumor activity of MSX-122 3. To perform correlative studies to elucidate signaling pathways involved in CXCR4 activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA (reverse phase protein microarrays)

NCT ID: NCT00591357 Suspended - Clinical trials for Clostridium Difficile

Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy

loperamide
Start date: October 2007
Phase: Phase 4
Study type: Interventional

To determine whether symptomatic treatment of the diarrhea in CDAD reduces morbidity and mortality of this serious nosocomial infection in patients who have antibiotic-associated diarrhea. Both C. diff positive and negative patients will be included.

NCT ID: NCT00587457 Suspended - Leukemia, Lymphoma Clinical Trials

A Phase I,Multicenter, Dose Escalation Study of CAT-8015 in Patients With Chronic Leukemia

Start date: March 2007
Phase: Phase 1
Study type: Interventional

To demonstrate the safety of CAT-8015 at MTD dose.

NCT ID: NCT00571272 Suspended - Liver Diseases Clinical Trials

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)

LOGIC
Start date: November 30, 2007
Phase:
Study type: Observational

Cholestasis is a condition in which bile is not properly transported from the liver to the small intestine. Cholestasis can be caused by an array of childhood diseases, including the genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acid synthesis and metabolism defects, and progressive familial intrahepatic cholestasis (PFIC) or benign recurrent intrahepatic cholestasis(BRIC). This study will investigate the natural history and progression of the four previously mentioned cholestatic liver diseases to provide a better understanding of the causes and effects of the diseases.

NCT ID: NCT00566514 Suspended - Fibromyalgia Clinical Trials

The Role of Ribose in Patients Diagnosed With Fibromyalgia

Start date: July 2006
Phase: N/A
Study type: Interventional

The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

NCT ID: NCT00549627 Suspended - Clinical trials for Posterior Spinal Fusion

Evaluation of the PediGuardâ„¢ for Pedicle Screw Insertion

Start date: August 2005
Phase: N/A
Study type: Interventional

The aim of the study is to determine the relative effectiveness of the PediGuardTM , a device manufactured by SpineVision, Inc, for placement of a pedicle screw pilot (drill) hole and for reducing pedicle screw breaches during thoracic and lumbar pedicle screw fixation of the spine. Hypothesis #1 The PediGuardTM will be more accurate for pedicle screw placement as compared to other standard manual techniques of similar size of pedicle screw insertion. At least 90% of screws placed with the PediGuardTM will be positioned correctly in the pedicle (defined as less than 2 mm breach by CT scan). In contrast, only 80% of screws using manual placement will be positioned correctly in the pedicle. Hypothesis #2 The PediGuardTM will not be inferior to fluoroscopic techniques for pedicle screw insertion. Both techniques will achieve at least 90% accuracy in the placement of pedicle screws.

NCT ID: NCT00546455 Suspended - Obesity Clinical Trials

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Start date: December 2007
Phase: Phase 2
Study type: Interventional

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.